NCT00386373View on ClinicalTrials.gov

Use and Tolerability of Imatinib Mesylate (Gleevec) in Leukemia Patients

NACompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

August 31, 2003

Primary Completion Date

October 31, 2007

Study Completion Date

October 31, 2007

Conditions
Leukemia
Interventions
DRUG

Imatinib Mesylate

Starting dose of 100 mg daily by mouth for first 100 days following bone marrow transplant (BMT) or stem cell transplant (SCT).

Trial Locations (1)

77030

U.T.M.D. Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER

NCT00386373 - Use and Tolerability of Imatinib Mesylate (Gleevec) in Leukemia Patients | Biotech Hunter | Biotech Hunter